Biotechnology
Merz and Israeli Start-Up Vensica Launch Partnership for Needleless Treatment of Overactive Bladder
11/08/2021 — FRANKFURT, Germany — (BUSINESS WIRE) wMerz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins, and the Israeli start-up Vensica Therapeutics Ltd., […]
Ultivue Announces Co-Marketing Agreement with Fluidigm for Biomarker Imaging Solutions for Precision Medicine
05/08/2021 — CAMBRIDGE, Mass. & SOUTH SAN FRANCISCO, Calif. — (BUSINESS WIRE) Ultivue, Inc. and Fluidigm Corporation (Nasdaq:FLDM) today announced a co-marketing agreement in which the companies will offer customers […]
Personalis, Inc. Publishes New Data Demonstrating a Novel Composite Biomarker NEOPS™ for Predicting Response to Cancer Immunotherapy in Late-Stage Melanoma Patients
02/08/2021 — MENLO PARK, Calif. — (BUSINESS WIRE) Personalis, Inc. (Nasdaq: PSNL), a leader in advanced translational genomics and diagnostics for cancer, today announced the publication of its study “Prediction […]
Adagio Therapeutics Appoints Leading Pharmaceutical and Regulatory Executives to its Board of Directors
29/07/2021 — WALTHAM, Mass, — (BUSINESS WIRE) Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, […]
Adagio Therapeutics Partners with Biocon Biologics to Bring Potent and Broadly Neutralizing COVID-19 Antibody Treatment to Patients in India and Select Emerging Markets
26/07/2021 — WALTHAM, Mass. — (BUSINESS WIRE) Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, […]
Adagio Therapeutics Appoints David Hering, Global COVID-19 Vaccine Expert, as Chief Operating Officer
19/07/2021 — WALTHAM, Mass. — (BUSINESS WIRE) Adagio Therapeutics, Inc., a biotechnology company developing highly differentiated antibodies to broadly neutralize coronaviruses, today announced that David Hering has been appointed as […]
Greek National Organization of Medicines Approves First Antimicrobial Formula for Residual Surface Protection Against SARS-CoV-2 (COVID-19 Virus) for up to 90 Days
US-Greek Partnership to Commercialize BIOPROTECT™ RTU to Meet Growing European Demand and Expand Demand outside the United States 14/07/2021 — PHILADELPHIA — (BUSINESS WIRE) ViaClean Technologies, LLC, a Philadelphia-based biotech […]
McKesson Corporation Enters Agreement to Sell Certain European Businesses to the PHOENIX Group
Transaction enhances McKesson’s focus and commitment to future investments in strategic growth, including oncology and biopharma services, and core pharmaceutical and medical distribution Agreement includes the sale of McKesson Europe […]
Personalis Announces NeXT Level Biomarkers Symposium
22/06/2021 — MENLO PARK, Calif. — (BUSINESS WIRE) Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced its inaugural event, NeXT Level Biomarkers Symposium, which will […]
Anna Biosciences Launches Pioneering Immunotherapeutic Treatment to Fight COVID-19
22/06/2021 — DUBLIN — (BUSINESS WIRE) Anna Biosciences, a drug discovery company focused on novel therapies in immuno-oncology, virology, and neurodegenerative diseases, today announces its entry in the fight against […]
Centessa Announces Pricing of Initial Public Offering
28/05/2021 — CAMBRIDGE, Mass. & LONDON — (BUSINESS WIRE) Centessa Pharmaceuticals plc (“Centessa”), a clinical-stage company employing its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines […]
Medicago and GSK Announce Positive Interim Phase 2 Results for Adjuvanted COVID-19 Vaccine Candidate
Similar antibody response in adults and in the elderly after two doses Neutralizing antibody responses were 10 times higher than people recovering from COVID-19 No related severe adverse events reported […]
Personalis, Inc. to Present at Biomarkers Week Online 2021
17/05/2021 — MENLO PARK, Calif. — (BUSINESS WIRE) Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will present at Biomarkers Week Online […]
Centessa Pharmaceuticals Announces Expansion of Management Team and Board of Directors
New Appointments Bring Expertise and Proven Leadership to Support Asset-Centric R&D Model and Portfolio Advancement 17/05/2021 — CAMBRIDGE, Mass. & LONDON — (BUSINESS WIRE) Centessa Pharmaceuticals (“Centessa”) today announced key […]
Centessa Pharmaceuticals Appoints One of the World’s Leading Drug Developers, Antoine Yver, M.D., M.Sc., as Chief Medical Officer
10/05/2021 — CAMBRIDGE, Mass. & LONDON, — (BUSINESS WIRE) Centessa Pharmaceuticals (“Centessa”) today announced that Antoine Yver, M.D., M.Sc., has been appointed as Chief Medical Officer. Dr. Yver is one […]
Aptorum Group Enters into an Agreement with Exeltis to Develop Aptorum’s Novel Preclinical Candidate Targeting Woman’s Gynecological Conditions
06/05/2021 — NEW YORK & LONDON & PARIS — (BUSINESS WIRE) Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, has […]
Adagio Therapeutics Announces ADG20 Phase 1 Data and Initiation of Global Phase 2/3 Clinical Trial of ADG20 for the Prevention of COVID-19
Preliminary Data from Ongoing Phase 1 Trial in Healthy Volunteers Support ADG20 Safety and Pharmacokinetic Profile and SARS-CoV-2 Neutralizing Activity Phase 2/3 EVADE Trial to Evaluate ADG20 for the Prevention […]
Ultivue Announces $50M Financing Round
27/04/2021 — CAMBRIDGE, Mass. — (BUSINESS WIRE) Ultivue, a leader in advancing precision medicine solutions through a unique approach that combines multiplex biomarker analysis with same slide traditional H&E for […]
Adagio Therapeutics Announces $336 Million Series C Financing to Support Rapid Advancement of Novel ADG20 #Antibody for the Treatment and Prevention of #COVID-19
Additional Capital to Fund Ongoing STAMP Pivotal Trial of ADG20 Designed to Support Emergency Use Authorization Submission Financing Follows First Quarter Appointment of Industry and Banking Veteran Jane Henderson as […]
LintonPharm Announces Authorization from China Health Authority (NMPA) to Proceed with a Phase 1/2 Trial Evaluating Catumaxomab for the treatment of Non-Muscle Invasive Bladder Cancer
13/04/2021 — GUANGZHOU, China — (BUSINESS WIRE) LintonPharm Co., Ltd., a China-based clinical stage biopharmaceutical company focused on the development of T cell engaging bispecific antibodies for cancer immunotherapy, today […]
Adagio Therapeutics Initiates Global Clinical Trial of ADG20 as a Treatment for COVID-19
Phase 1/2/3 STAMP Trial to be Conducted Globally, Including in Countries with High Rates of SARS-CoV-2 Variants Resistant to Other Monoclonal Antibody Products Potential for Early Access to Therapy by […]
Medicago and GSK Start Phase 3 Trial of Adjuvanted COVID-19 Vaccine Candidate
Trial to enroll up to 30,000 volunteers worldwide Fast Track designation granted by US FDA Feasibility study initiated of a vaccine candidate to address emerging variants 16/03/2021 — QUEBEC CITY […]
Daiichi Sankyo Appoints Ken Takeshita, MD as Global Head of R&D
22/02/2021 — TOKYO & MUNICH & BASKING RIDGE, N.J. — (BUSINESS WIRE) Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced Ken Takeshita, MD will be named the new Global […]
Natera and Personalis Partner for Personalized Monitoring in Oncology
17/02/2021 — MENLO PARK, Calif. & SAN CARLOS, Calif. — (BUSINESS WIRE) Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, and Natera, Inc. (Nasdaq: NTRA), a global […]
Centessa Pharmaceuticals Launches with $250 Million Series A Financing and Unveils a New Kind of Pharmaceutical R&D Model
Merger of 10 Privately Held Biotech Companies with Highly Validated Programs Led by Industry Leading Teams to Operate Under Centessa Umbrella Company Founded by Medicxi with Financing Led by General […]
European Commission Approves Seagen’s TUKYSA® (tucatinib) for the Treatment of Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer
– Approved for Adult Patients with HER2-Positive Metastatic Breast Cancer Who Have Received at Least Two Prior Anti-HER2 Treatment Regimens – – First HER-2 Tyrosine Kinase Inhibitor Combination Regimen to […]
Xeris Pharmaceuticals Receives European Commission Approval of Ogluo™ (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus
OGLUO™ Europe’s first and only ready-to-use liquid glucagon for rescue First availability expected in the fourth quarter Approval supported by data from pivotal Phase 3 study 12/02/2021 — CHICAGO & […]
Quotient Sciences Acquires Arcinova, the UK-Based Contract Development and Manufacturing Organization
09/02/2021 — NOTTINGHAM, England — (BUSINESS WIRE) Quotient Sciences, the drug development and manufacturing accelerator, announced that it has acquired Arcinova, the U.K.-based multiservice contract development and manufacturing organization (CDMO). […]
MED™ 3D Printed Pharmaceutical Product Receives IND Clearance From the US FDA
Triastek Opens a New Chapter for Digital Formulation Development and Intelligent Pharmaceutical Manufacturing 09/02/2021 — NANJING, China — (BUSINESS WIRE) Triastek, Inc. (“Triastek”), a pharmaceutical company specializing in 3D printing […]
Mawi DNA’s Extractionless Sample Collection Technology Enables BioTech Africa Launch of Affordable COVID-19 Mass Testing Platform
25/01/2021 — HAYWARD, Calif. — (BUSINESS WIRE) Mawi DNA Technologies’ iSWAB-Microbiome-EL sample collection technology enables BioTech Africa to implement and launch a new ultra-high throughput COVID-19 testing program. This breakthrough, […]